Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPV and bOPV Immunogenicity in Infants
NCT02291263Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Oct 2014
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trivalent inactivated polio vaccine in poliomyelitis (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Change in antibody titers at 19 weeks. Started Oct 2014; status: completed.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02291263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291263.